Back to Treatments

Treatment

Nivolumab (PD-1 inhibitor)

1
Conditions
14
Trials
3,000
Participants
45%
Average Safety

Condition Evidence

Hodgkin lymphoma

14 trials · 3,000 participants

70% effectiveness · 45% safety
Nivolumab (PD-1 inhibitor) | DFDA